SciBase has received the first commercial order in the US – from a private clinic with a focus on self-pay patients in Manhattan, New York.
The order, consisting of a Nevisense system and single-use electrodes, is strategically important for the company as it can be seen as an early sign that their launch strategy is the right approach. SciBase’s strategy focuses initially on marketing Nevisense to private clinics with self-pay patients in the New York Metropolitan Area.
“We are very pleased to have sold our first Nevisense in the US and take it as an early confirmation that our US strategy is the right one. This is a great clinic to start with and we will be gearing up our efforts going forward,” says Simon Grant, CEO SciBase.